NanoPass Technologies Ltd. is a pioneer in intradermal delivery, leveraging its proprietary MicronJet™ platform—the first FDA-cleared true intradermal delivery technology (<1 mm)—to transform treatments across both medical and aesthetic fields.

With over 70 clinical studies, the company is at the forefront of improving vaccines immunotherapies, and drug delivery.

In parallel, NanoPass has brought its innovation to the aesthetic landscape, with millions of successful treatments worldwide, where MicronJet™ provides physicians and patients with a new standard of safety, precision, and comfort—minimizing bruising, pain, and downtime while enabling consistent delivery of bioactive materials such as skin boosters, polynucleotides, PRP, and other intradermal treatments.

Today, NanoPass operates globally in more than 30 countries, partnering with leading pharmaceutical and aesthetic brands, and continues to set benchmarks for evidence-based, patient-centric delivery solutions.

Our vision

To redefine intradermal delivery as the gold standard for precision, safety, and patient comfort — empowering better healthcare, aesthetic outcomes, and quality of life. We envision a world where every treatment, from life-saving vaccines to advanced aesthetic solutions, is delivered more effectively and more humanely through NanoPass’s innovation.